Elevance Health (ELV) News
Filter ELV News Items
ELV News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ELV News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest ELV News From Around the Web
Below are the latest news stories about ELEVANCE HEALTH INC that investors may wish to consider to help them evaluate ELV as an investment opportunity.
Does Elevance Health (NYSE:ELV) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the... |
Elevance Health to Hold Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2024 Results on January 23, 2025INDIANAPOLIS, January 09, 2025--Elevance Health (NYSE: ELV) will release fourth quarter and full year 2024 financial results on January 23, 2025, at 6:00 a.m. Eastern Standard Time ("EST"). Management will review these results and its outlook during a conference call at 8:30 a.m. EST that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: |
Elevance Health, Inc. (ELV): A Bull Case TheoryWe came across a bullish thesis on Elevance Health, Inc. (NYSE:ELV) on Substack by Waterboy Investing. In this article, we will summarize the bulls’ thesis on ELV. Elevance Health, Inc. (NYSE:ELV)’s share was trading at $383.24 as of Jan 9th. ELV’s trailing and forward P/E were 13.95 and 10.98 respectively according to Yahoo Finance. Elevance Health Inc., […] |
Is Now An Opportune Moment To Examine Elevance Health, Inc. (NYSE:ELV)?Elevance Health, Inc. ( NYSE:ELV ) received a lot of attention from a substantial price movement on the NYSE over the... |
Elevance Health price target lowered to $480 from $520 at TruistTruist lowered the firm’s price target on Elevance Health (ELV) to $480 from $520 and keeps a Buy rating on the shares as part of a broader research note previewing 2025 for Healthcare Services. The firm sees the outlook for the group as “mixed”, with bullish stance on the underlying demand drivers and overarching sector tailwinds that include demographics, value-based care, and core demand being offset by heightened concern around a likely more cost focused government backdrop. Selectivity is k |
Healthcare Executives Bullish on 2025: But Why Are Stocks Slipping?Improving the consumer experience, engagement and trust is emerging as a top strategy for healthcare companies. |
Investors in Elevance Health (NYSE:ELV) have unfortunately lost 24% over the last yearThe simplest way to benefit from a rising market is to buy an index fund. Active investors aim to buy stocks that... |
Elevance Health, Inc. (ELV): Among the Cheap Healthcare Stocks to Buy Heading Into 2025We recently compiled a list of the 12 Cheap Healthcare Stocks to Buy Heading into 2025. In this article, we are going to take a look at where Elevance Health, Inc. (NYSE:ELV) stands against the other cheap healthcare stocks. The Resilience and Challenges of Global Healthcare Spending Investing in healthcare equities is typically seen as protective […] |
Is Weakness In Elevance Health, Inc. (NYSE:ELV) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?Elevance Health (NYSE:ELV) has had a rough three months with its share price down 29%. But if you pay close attention... |
Novo Nordisk is 'losing its pep' in GLP-1 race: BMO analystComing off of Novo Nordisk's (NVO) sharp stock decline after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted, BMO Capital Markets cut its price target on the pharmaceutical company from $156 to $105 per share. "This was supposed to be Novo's answer to Tirzepatide and Retatrutide, some higher efficacy drugs, and it kind of feels like where no man's land here. So we're really focused on next year when it comes to 4Q results, that's going to set the tone for the commercial side of these products for both Lilly and Novo," BMO Capital Markets managing director of biopharma equity research Evan Seigerman explains. "And then mid-year for Lilly, we have Orforglipron, which is their small molecule pill GLP-1, which could really... |